Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Smoking Cessation for Yale Dining Employees
NCT02562521Phase 4Completed
- Sponsor
- Yale University
- Start
- Sep 2015
- Primary completion
- Dec 2016
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of nicotine patch and varenicline + nicotine patch in Tobacco Use Disorder (TUD) (2 arms), sponsored by Yale University. Primary endpoints: Number of Participants With a Smoking Quit Attempt in the Prior Six Weeks at 6 weeks and Number of Participants Who Quit Smoking for at Least 24 Hours in the Prior Six Weeks. Started Sep 2015; status: completed.
02
Drugs
nicotine patchvarenicline + nicotine patch
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT02562521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02562521.